- BioPharm International-12-02-2006
- Volume 2006
- Issue 7
Scotland: Ushering in the next age of life sciences
Scotland is a recognized leader in stem cell research, neuroscience, cancer research, genomics, proteomics, and bioinformatics.
With continued success over the last few years, Scotland's life sciences sector is thriving and has a very promising future in sight. The country's growth in this sector can be attributed to major breakthroughs in several research areas and international partnerships. With continued advances in science, however, come several changes to the life sciences globally. Methods of diagnosing and treating diseases will undoubtedly change as a result of the sequencing of the genome and as the genetic basis of more and more diseases is revealed. The use of nanotechnology will allow more targeted drug delivery, and new technologies are allowing medical devices to be less invasive and more site-specific. Other major shifts have included increased outsourcing of R&D and the integration of pharmaceutical and biotechnology companies to meet the rise in demand of un-met medical needs more efficiently. Scotland is eager to capitalize on these global changes as many of country's strengths lie in these very areas.
Ken Snowden
Scotland's life sciences sector comprises more than 590 organizations, with nearly 29,500 employees. The country is making significant contributions to biomedical research and is already recognized as a leader in stem cell research, neuroscience, cancer research, genomics, proteomics, and bioinformatics. With a strong research base, an excellent academic community, and home to many of the world's leading experts in their respective fields, Scotland is and will continue to be a premier choice for research partnerships and global expansions.
INTERNATIONAL COLLABORATIONS
Recently, Invitrogen Corporation (
In April 2006, another major announcement was made that will solidify Scotland's role as a leader in not only developing innovative treatments for some of the world's most debilitating diseases, but also for speeding up the process of bringing them from bench to bedside. This deal, worth approximately $95 million, was signed by Wyeth Pharmaceutical Co. (
STEM CELL RESEARCH
Perhaps one of the most challenging but ultimately promising areas of study in this century is stem cell research. Scotland is already well distinguished in this field and will continue advancing the applicability of stem cells in treating several of the world's deadliest diseases.
Aside from being home to many of the top stem cell experts and having an unmatched academic environment, the country has a favorable regulatory environment, funding support from its government, and some of the most advanced research facilities in the world.
In late 2006, Roslin Cells (
This activity also reinforces Scotland's role in facilitating stem cell research, allowing scientists to access human stem cell lines on a non-profit basis and help start-up companies enter the stem cell arena.
ACADEMIC EXCELLENCE
Scotland's academic community offers industry the solid research foundation it needs to thrive in competitive markets. International life sciences powerhouses have sought out Scottish universities to facilitate progress in targeted industry areas. Geron Corporation (
Another major collaboration is at University of Dundee's (
THE FUTURE
Scotland's leading status in the life sciences will be strengthened in the coming years with several new developments in the pipeline, giving Scotland a new national identity as a life sciences hub. Under the new "Life Sciences Scotland" brand (
Among the strongest assets strengthening the Life Sciences Scotland brand will be the new Center for Biomedical Research (
Additionally, the Life Sciences Alliance, formed last year and comprising senior representatives from the key public and private sector organizations involved in Scotland's Life Sciences, will aim to encourage closer working relationships among industry, academia, the National Health Service, and policy makers at a national level to facilitate Scottish innovation well into the twenty-first century.
KEN SNOWDEN is the director of life sciences for Scottish Enterprise, 150 Broomielaw, Atlantic Quay, Glasgow, Scotland, G2 8LU, tel. +141 228 2499,
Articles in this issue
almost 19 years ago
Stem Cell Industry Puts Scotland in the Spotlightalmost 19 years ago
The Next Generation: Scottish R&D in Life Sciencesalmost 19 years ago
The Talent Poolalmost 19 years ago
A Capable Communityalmost 19 years ago
The Grand Alliancesalmost 19 years ago
Centers of Excellencealmost 19 years ago
Revolutionizing Translational Medicine through CollaborationsNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.